Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
touched 1.47,,,,,, 1.45 is middle bollie on the 10min
Looks like they diluting
News: $CHFS CHF Solutions, Inc. Announces Sales Force Realignment To Increase Focus On Cardiac Surgery And Eventually Pediatrics
EDEN PRAIRIE, Minn., Nov. 01, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS), a medical device company focused on developing, manufacturing and commercializing a clinically proven solution for diuretic-resistant patients suffering from fluid overload, announced a sales force re...
Got this from CHFS - CHF Solutions, Inc. Announces Sales Force Realignment To Increase Focus On Cardiac Surgery And Eventually Pediatrics
1.53 looks bottom on that dip got some 1.59
I saw this this am and rode it to 1.6, should’ve just held till next week, I’ll buy again if it dips, looking great however, such a huge profit potential here, damm! Good luck to those holding
Cool off then resume this one's a runner
I guess we see some churn... and then a leg to 2
wow CHFS
looks like it wants 2's
And way more... it could ;)
Could hit 2.00 plus
Yeah super sweet float... may 1,80+ today... could also turn into a real monster
Nice going bud! > moving up like rocketship.
Nice going bud! > moving up like rocketship.
4,5 Milli volume First 5 minutes lol
Woooowzaaaa,moving strong
Interesting on CEO John Erb. > Today's news is powering CHFS up in PM.
News: $CHFS Multi-Center, Retrospective Study Evaluates Use of Ultrafiltration Therapy with Aquadex FlexFlow® System in Pediatric Patients
EDEN PRAIRIE, Minn., Sept. 24, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced the publication of a multi-center, retrospective study in the Clinical Journal of the American Society of Nephrology 1 evaluating the use of hemofiltration and ultrafiltration therapy ...
Got this from CHFS - Multi-Center, Retrospective Study Evaluates Use of Ultrafiltration Therapy with Aquadex FlexFlow® System in Pediatric Patients
Multi-Center, Retrospective Study Evaluates Use of Ultrafiltration Therapy with Aquadex FlexFlow® System in Pediatric Patien...
Print
Alert
CHF Solutions (NASDAQ:CHFS)
Intraday Stock Chart
Today : Tuesday 24 September 2019
Click Here for more CHF Solutions Charts.
CHF Solutions, Inc. (Nasdaq:CHFS) today announced the publication of a multi-center, retrospective study in the Clinical Journal of the American Society of Nephrology1 evaluating the use of hemofiltration and ultrafiltration therapy with the company’s Aquadex FlexFlow system in pediatric patients. The Aquadex FlexFlow system is not yet cleared by FDA for use in pediatric patients.
The study, titled “Kidney Support in Children Using an Ultrafiltration Device,” included 117 patients in three weight categories: <10 kgs; 10-20 kgs; and >20 kgs, suffering from volume overload, acute kidney injury or end-stage kidney disease. All patients across the three weight categories were treated with the Aquadex FlexFlow system, using one of the following three modalities: slow continuous ultrafiltration (SCUF); continuous veno-venous hemofiltration (CVVH); or prolonged intermittent kidney replacement therapy, based on patient condition.
The primary outcome was survival to the end of therapy. In patients weighing over 20 kgs (n=32), 97% survived to the end of therapy. In patients weighing between 10-20 kgs (n=13), 100% survived to the end of therapy. In patients weighing under 10 kgs (n=72), 60% survived to the end of therapy.
“We report the first multi-center experience in pediatrics in which we use an ultrafiltration device to provide kidney support therapy in younger patients," said David Askenazi, M.D., M.S.P.H., Professor of Pediatrics at the University of Alabama Birmingham/Children’s of Alabama. “For many of the types of patients in the study, available therapies require very high relative extracorporeal blood volumes, which can be challenging. With the use of an ultrafiltration device with a small blood volume, we were able to initiate therapy with excellent hemodynamic stability.”
As previously announced, the company will be hosting a conference call and webcast with investigators from the study tomorrow, September 25, at 1:00 pm Eastern Time. To access the live webcast, please visit the Investors page of the CHF Solutions website at http://ir.chf-solutions.com or access the webcast directly at http://ir.chf-solutions.com/events. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 6985754. An audio archive of the webcast will be available following the call on the Investor page at http://ir.chf-solutions.com/events.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on developing, manufacturing and commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is a clinically proven therapy that provides a safe, effective, and predictable method of removing excess sodium and fluid from patients suffering from fluid overload. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. CHF Solutions expects to submit an application to the FDA requesting a modification to the 510(k) clearance for the Aquadex FlexFlow system to include pediatric patients above 20kg in the near future. The company is dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovative. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
Wow, Erb and Drayton are two thieves. They are in this for themselves and maybe a few close ties. Investors they've used and abused... I believe everyone who held here since SSH change of name and direction has lost -99% on top of the SSH losses of probably another -99%.... all the while they've taken HUGE SALARIES and other means of screwing Investors out of money. I would not put it past them if they are in with shorting the stock indirectly because this is their character... shysters in sheep clothing. They should be JAILED.
Here's Some Projections based off facts and Proof:
See Heinz yahoo mb under CHFS postings....
https://prnt.sc/nm2rmr
CHFS looks like a nice play right now. Only 600 000 shares available
News: $CHFS CHF Solutions to Exhibit at The International Society for Heart and Lung Transplantation 2019 Annual Meeting and Scientific Sessions
EDEN PRAIRIE, Minn., March 28, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), today announced it will be exhibiting at the 2019 Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) on April 3-6, 2019 at the Lowes Meeting Comp...
In case you are interested https://marketwirenews.com/news-releases/chf-solutions-to-exhibit-at-the-international-society-for-heart-and-lung-transplantation-2019-annual-meeting-and-scientific-sessions-7906018.html
$17-$20 moving average.
Wonder if it will Squeeze Higher!?
Ma200 is a mile high Blue sky Up.
Stocks called out was GBTC under $150 and ran to $3500.
That was the biggest move I've seen in a long time.
***$8 Gap fill and $17-20 MA's ***
It was never pumped though. Barely any volume. For a low floaters they could’ve pumped it real hard and didn’t do anything
Market tells you what they think. This company (or their underwriters) will pump up their stock price just prior to PP announcement and then it crashes after the news. I would NEVER go near this stock. I have never owned it to follow it for some reason.
David.
Yup. I guess an RS to bring the price all the way up to $10 was to facilitate an offering. Either way, super low float and those 130k shares will likely convert very quickly. Might be a good bounce play coming from sub $5
No wonder CHFS dumped today!
CHF Solutions, Inc. Announces Pricing of $10.8 Million Underwritten Public Offering
EDEN PRAIRIE, Minn., March 08, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $10.8 million prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions.
The offering is comprised of (1) 146,607 Class A Units, priced at a public offering price of $5.25 per unit, with each unit consisting of one share of common stock, a Series 1 warrant to purchase one share of common stock at an exercise price of $5.25 per share that expires on the fifth anniversary of the date of issuance and a Series 2 warrant to purchase one share of common stock at an exercise price of $5.25 per share that expires on the earlier of the eighteen-month anniversary of the date of issuance and the 30th trading day following public announcement by CHF Solutions of receipt from the U.S. Food and Drug Administration (FDA) of clearance or approval of a modification to the product label for the Aquadex FlexFlow® system to include pediatric patients, and (2) 1,910,536 Class B Units, priced at a public offering price of $5.25 per unit, with each unit consisting of one share of Series G convertible preferred stock, convertible into one share of common stock, a Series 1 warrant to purchase one share of common stock with an exercise price of $5.25 per share and a Series 2 warrant to purchase one share of common stock with an exercise price of $5.25 per share.
The conversion price of the preferred stock issued in the transaction as well as the exercise price of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock) or liquidation preference, and, subject to limited exceptions, has no voting rights. The securities comprising the units are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about March 12, 2019, subject to the satisfaction or waiver of customary closing conditions.
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American: LTS), is acting as sole book-running manager in connection with the offering.
A total of 146,607 shares of common stock, 1,910,536 shares of Series G convertible preferred stock, Series 1 warrants to purchase up to 2,057,143 shares of common stock and Series 2 warrants to purchase up to 2,057,143 shares of common stock will be issued in the offering. In addition, the Company has granted the underwriters a 45-day option to purchase up to 308,571 additional shares of common stock, additional Series 1 warrants to purchase up to 308,571 shares of common stock and/or additional Series 2 warrants to purchase up to 308,571 shares of common stock solely to cover over-allotments, if any, at the public offering price per share and per warrant, less the underwriting discounts and commissions.
The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-229102), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on March 7, 2019 and an additional registration statement filed pursuant to Rule 462(b) (File No. 333-230142), which became effective when filed.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering is being made solely by means of a prospectus. A final prospectus relating to this offering will be filed by CHF Solutions with the SEC. When available, copies of the final prospectus can be obtained at the SEC’s website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172 or by email at prospectus@ladenburg.com.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
On watch. Nice pullback to sub $10. Could be worth a long position
I filled Fri my first order. 513,000 O/S, 5.5 mil cash, 0 debt.
CHF Solutions, Inc. Announces 80% Revenue Growth for its Fourth Quarter and Provides Company Update
EDEN PRAIRIE, Minn., Feb. 20, 2019 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter and year ended December 31, 2018, which included the following highlights:
Revenue for the fourth quarter ended December 31, 2018 increased 80.4 percent compared to the same period in 2017. Revenue growth for the year 2018 was 40.7 percent compared to the year 2017.
Continued marketing focus into post-cardiovascular surgery and heart failure outpatient clinics.
Commenced discussions with the FDA to request a label modification to include pediatrics.
Continued international expansion with announcement of new distributor agreements in India and Brazil.
Announced the filing of two new patent applications to deepen the company’s intellectual property protection of its Aquadex Flexflow® system.
Ended the quarter with $5.5 million in cash and cash equivalents and no debt.
“Our fourth quarter and year-end performance reflects the significant work our team accomplished during 2018. We achieved impressive revenue growth and continued to make strides in our commercialization efforts,” said John Erb, chairman and CEO of CHF Solutions. “I look forward to executing on the additional market opportunities we have identified, which we believe will deliver additional growth in 2019 and beyond.”
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit http://ir.chf-solutions.com/events. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 4589101. An audio archive of the webcast will be available following the call at http://ir.chf-solutions.com/events.
Low float 510k OS.
Low market cap $5.3mm.
Warrants at $29 and $50.
Let’s go ??
Carl Icahn took position today (Jan 3rd)
I'm curious as to what the R/S ratio will end up being.... Tick tock
Correction.... December 28th to be correct.
R/S incoming once approved on Dec 8th... Glad I held off the trigger!
Followers
|
65
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1655
|
Created
|
07/06/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |